eCite Digital Repository

Highly Active Antiretroviral Therapy: Pharmacoeconomic issues in the management of HIV infection

Citation

Sendi, P and Palmer, AJ and Gafni, A and Battegay, M, Highly Active Antiretroviral Therapy: Pharmacoeconomic issues in the management of HIV infection, Pharmacoeconomics, 19, (7) pp. 709-713. ISSN 1170-7690 (2001) [Refereed Article]

DOI: doi:10.2165/00019053-200119070-00001

Abstract

The advent of highly active antiretroviral therapy (HAART), including protease inhibitors and/or non-nucleoside reverse transcriptase inhibitors, for the treatment of HIV infection has led to a dramatic decline of morbidity and mortality. The acquisition costs of HAART are substantial. However, these costs are partially offset by reduced inpatient care for opportunistic infections and other AIDS-related diseases. Furthermore, job productivity in patients infected with HIV is increased under HAART. In developed countries with a low unemployment rate, the discounted value of savings caused by increased productivity in earlier years exceeds the discounted value of later increases in costs resulting from morbidity. Therefore, HAART represents a very efficient treatment strategy that leads to overall cost savings when taking a societal perspective.

Item Details

Item Type:Refereed Article
Research Division:Economics
Research Group:Applied Economics
Research Field:Health Economics
Objective Division:Health
Objective Group:Health and Support Services
Objective Field:Health Policy Economic Outcomes
Author:Palmer, AJ (Professor Andrew Palmer)
ID Code:74724
Year Published:2001
Web of Science® Times Cited:23
Deposited By:Research Division
Deposited On:2011-12-12
Last Modified:2011-12-13
Downloads:0

Repository Staff Only: item control page